William P. Vaughan, MD
Division: Hematology & Oncology
Campus Address: THT 541
1720 2nd Avenue South, THT541
Birmingham, AL 35294-0006
Phone: (205) 934-1908
Secondary: Pharmacology & Toxicology
University of Connecticut School of Medicine
Internal Medicine Residency:
University of Chicago Hospitals and Clinics
Oncology & Internal Medicine, The Johns Hopkins University of Medicine
MBA, University of Alabama, Tuscaloosa
William Vaughan, MD, MBA is Professor of Internal Medicine and Pharmacology and Director of the Cell Therapy and Transplantation Program at UAB. His early research was in basic immunology at the Trudeau Institute while in medical school. As a Fellow and junior faculty member at Johns Hopkins from 1975 through 1983 and as Medical Director of the Bone Marrow Transplant Program at Nebraska from 1983 through 1991 he conducted laboratory and clinical investigation in cancer pharmacology and cell kinetics. Recruited to UAB in 1991 to establish a BMT program here, he continued his clinical trial work in high dose chemotherapy and hematopoietic stem cell transplantation. He is recognized as a national and international leader in the development of safer preparative regimens for bone marrow transplantation through pharmacokinetics directed dosing. He currently holds an FDA IDE for a clinical trial to permit individualization of the cellular content of peripheral stem cell grafts for allogeneic HSCT. His research has been funded by the NCI, the American Cancer Society and others. He is an author of more than 120 original papers, reviews and monographs in basic and applied science relevant to blood, stem cell, and immune system diseases as well as cancer. He is an author of more than 160 presentations at scientific meetings. He has been a reviewer or on the editorial board of multiple scientific journals including JCO and Blood. He has been a member or chairman of multiple advisory panels and review committees for the NCI. He has been an officer of several national organizations including immediate past Chairman of the Board of NCCN. He has consulted for Bristol Myers Squibb, Merck, Genzyme, Shering-Plough and others, and more extensively for Amgen and Orphan Medical. He has presented to the FDA Oncology Drug Advisory Committee.
Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.